A Phase 2 study of TP-04 for treatment of Rosacea
Latest Information Update: 27 Jan 2025
Price :
$35 *
At a glance
- Drugs Lotilaner (Primary)
- Indications Rosacea
- Focus Therapeutic Use
- 27 Jan 2025 New trial record
- 13 Jan 2025 According to a Tarsus Pharmaceuticals media release, Based on FDA feedback, the Company has established a clear regulatory path forward for TP-04 and plans to initiate a Phase 2 study in the second half of 2025. Results are anticipated in 2026.